Literature DB >> 21919689

Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.

Theodore Liakakos, Dimitrios H Roukos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21919689     DOI： 10.2217/fon.11.88

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  4 in total

1.  Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.

Authors:  Aaron I Vinik; Eric Raymond
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

2.  A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations.

Authors:  Siddhartha Devarakonda; Bruna Pellini; Luke Verghese; Haeseong Park; Daniel Morgensztern; Ramaswamy Govindan; Rama Suresh; Peter Oppelt; Maria Q Baggstrom; Ningying Wu; Saiama N Waqar
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 3.005

Review 3.  Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors.

Authors:  Bin Ren; J Bart Rose; Yehe Liu; Renata Jaskular-Sztul; Carlo Contreras; Adam Beck; Herbert Chen
Journal:  J Clin Med       Date:  2019-11-14       Impact factor: 4.241

4.  Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.

Authors:  Huaqiang Zhou; Yuanzhe Zhang; Xiaoyue Wei; Kaibin Yang; Wulin Tan; Zeting Qiu; Si Li; Qinchang Chen; Yiyan Song; Shaowei Gao
Journal:  Cancer Med       Date:  2017-10-04       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.